Lexeo (LXEO) COO Jose Otero Receives Award, Buys ESPP Shares

What Happened

• Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), reported two acquisitions: a purchase of 2,110 common shares under the company’s Employee Stock Purchase Plan on 2026-09-14 at $2.64 per share (total $5,579), and a grant of 54,750 derivative securities on 2026-09-24 with a $0.00 purchase price (award/derivative).
• The ESPP purchase is an outright buy (cash outlay $5,579). The zero-cost, derivative grant is a compensation award that will be subject to vesting or exercise conditions described in the filing.

Key Details

• Transaction dates/prices: 9/14/2026 — 2,110 shares at $2.64 each ($5,579); 9/24/2026 — 54,750 derivative shares @ $0.00.
• Filing: Form 4 filed 2026-09-28 covering the 9/24/2026 report date — filed within the required 2 business days (timely).
• Holdings note: the filing’s footnote states reported holdings include 97,026 Restricted Stock Units (RSUs).
• Vesting/derivative terms: Footnote indicates a typical option vesting schedule — 25% vests on 9/24/2027, then 1/48th of the underlying shares vest monthly thereafter (subject to continued service).
• Exemptions: The ESPP purchase is reported as exempt under Rule 16b-3(c) and (d) per the filing (footnote F1).
• Transaction code: both entries reported as A (award/grant/acquisition).

Context

• The ESPP purchase is a direct purchase of stock and is often viewed as a stronger signal than awards because it involves personal cash investment; the award/derivative grant is part of compensation and will vest over time, so it does not represent immediate market selling or buying.
• No sale or cashless exercise was reported — the derivative award appears to be time‑based (vesting schedule applies). As always, awards can be routine comp/retention grants and do not by themselves indicate the insider’s view of near-term stock performance.